Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

Sponsor
AbbVie
Study ID
NCT02668640
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — BIOLOGICAL
    Pre-filled syringe, administered by subcutaneous injection

Study Details

The objective of this study was to assess the effectiveness of adalimumab on health and disability outcomes in participants with rheumatoid arthritis (RA) in China.

Key Dates

Start date
May 1, 2016
Status verified
Aug 2019
Primary completion
Jun 12, 2018
Completion
Aug 13, 2018

Study Design

Enrollment
55 participants (actual)

Arms

  • Arm: Participants with RA receiving adalimumab
    40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 24 weeks

Primary Outcome Measure

Median Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score at Week 24 [ Time Frame: Baseline and Week 24 ]

Related Studies